

Supplement S6: Supplementary Table: Venous Thromboembolisms and Serious Adverse Events – Full Analysis Set (FAS)

Adverse Events up to End of Study: SYSTEM ORGAN CLASS Preferred Term	Randomised Treatment	
	PLASMA + SOC	SOC
Total Number of Subjects	320	163
<b>DEEP VEIN THROMBOEMBOLISMS</b>		
Any Venous Thromboembolisms	1 ( 0.3%)	1 ( 0.6%)
Deep Vein Thrombosis	0 ( 0.0%)	0 ( 0.0%)
Pulmonary Embolism	1 ( 0.3%)	1 ( 0.6%)
<b>SERIOUS ADVERSE EVENTS BY MEDDRA SYSTEM ORGAN CLASS AND PREFERRED TERM</b>		
Number of subjects with Serious Adverse Events	66 ( 20.6%)	34 ( 20.9%)
Number of Serious Adverse Events	78	40
<b>INFECTIONS AND INFESTATIONS</b>		
COVID-19	20 ( 6.3%)	13 ( 8.0%)
Septic shock	2 ( 0.6%)	1 ( 0.6%)
Bronchopulmonary aspergillosis	1 ( 0.3%)	1 ( 0.6%)
COVID-19 pneumonia	2 ( 0.6%)	0 ( 0.0%)
Pneumonia	0 ( 0.0%)	2 ( 1.2%)
Sepsis	2 ( 0.6%)	0 ( 0.0%)
Aspergillus infection	1 ( 0.3%)	0 ( 0.0%)

Bacterial infection	1 ( 0.3%)	0 ( 0.0%)
Enterobacter pneumonia	1 ( 0.3%)	0 ( 0.0%)
Enterococcal sepsis	1 ( 0.3%)	0 ( 0.0%)
Pneumonia legionella	1 ( 0.3%)	0 ( 0.0%)
Pulmonary sepsis	0 ( 0.0%)	1 ( 0.6%)
Urinary tract infection bacterial	0 ( 0.0%)	1 ( 0.6%)
Viral infection	1 ( 0.3%)	0 ( 0.0%)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	12 ( 3.8%)	8 ( 4.9%)
Hypoxia	3 ( 0.9%)	1 ( 0.6%)
Respiratory failure	3 ( 0.9%)	1 ( 0.6%)
Dyspnoea	3 ( 0.9%)	0 ( 0.0%)
Dyspnoea exertional	2 ( 0.6%)	1 ( 0.6%)
Acute respiratory distress syndrome	0 ( 0.0%)	1 ( 0.6%)
Bronchopneumopathy	0 ( 0.0%)	1 ( 0.6%)
Dyspnoea at rest	1 ( 0.3%)	0 ( 0.0%)
Interstitial lung disease	0 ( 0.0%)	1 ( 0.6%)
Pulmonary alveolar haemorrhage	0 ( 0.0%)	1 ( 0.6%)
Pulmonary embolism	0 ( 0.0%)	1 ( 0.6%)
Pulmonary oedema	1 ( 0.3%)	0 ( 0.0%)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	12 ( 3.8%)	1 ( 0.6%)
Multiple organ dysfunction syndrome	4 ( 1.3%)	0 ( 0.0%)
Pyrexia	4 ( 1.3%)	0 ( 0.0%)
General physical health deterioration	3 ( 0.9%)	0 ( 0.0%)
Death	0 ( 0.0%)	1 ( 0.6%)
Disease progression	1 ( 0.3%)	0 ( 0.0%)

CARDIAC DISORDERS	2 ( 0.6%)	5 ( 3.1%)
Cardiac failure	2 ( 0.6%)	0 ( 0.0%)
Arrhythmia	0 ( 0.0%)	1 ( 0.6%)
Atrial fibrillation	0 ( 0.0%)	1 ( 0.6%)
Cardiac arrest	0 ( 0.0%)	1 ( 0.6%)
Cardio-respiratory arrest	0 ( 0.0%)	1 ( 0.6%)
Mitral valve incompetence	0 ( 0.0%)	1 ( 0.6%)
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	5 ( 1.6%)	0 ( 0.0%)
Transfusion reaction	3 ( 0.9%)	0 ( 0.0%)
Febrile non-hemolytic transfusion reaction	1 ( 0.3%)	0 ( 0.0%)
Transfusion related complication	1 ( 0.3%)	0 ( 0.0%)
GASTROINTESTINAL DISORDERS	2 ( 0.6%)	2 ( 1.2%)
Abdominal pain	1 ( 0.3%)	0 ( 0.0%)
Gastrointestinal haemorrhage	1 ( 0.3%)	0 ( 0.0%)
Intestinal obstruction	0 ( 0.0%)	1 ( 0.6%)
Melaena	0 ( 0.0%)	1 ( 0.6%)
INVESTIGATIONS	3 ( 0.9%)	1 ( 0.6%)
Oxygen saturation decreased	2 ( 0.6%)	0 ( 0.0%)
Pseudomonas test positive	1 ( 0.3%)	0 ( 0.0%)
SARS-CoV-2 test positive	0 ( 0.0%)	1 ( 0.6%)
NERVOUS SYSTEM DISORDERS	3 ( 0.9%)	1 ( 0.6%)
Ischaemic stroke	1 ( 0.3%)	1 ( 0.6%)
Guillain-Barre syndrome	1 ( 0.3%)	0 ( 0.0%)
Transient ischaemic attack	1 ( 0.3%)	0 ( 0.0%)
RENAL AND URINARY DISORDERS	2 ( 0.6%)	1 ( 0.6%)

Acute kidney injury	2 ( 0.6%)	0 ( 0.0%)
Urinary retention	0 ( 0.0%)	1 ( 0.6%)
BLOOD AND LYMPHATIC SYSTEM DISORDERS	1 ( 0.3%)	0 ( 0.0%)
Anaemia	1 ( 0.3%)	0 ( 0.0%)
METABOLISM AND NUTRITION DISORDERS	0 ( 0.0%)	1 ( 0.6%)
Fluid overload	0 ( 0.0%)	1 ( 0.6%)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	0 ( 0.0%)	1 ( 0.6%)
Metastatic neoplasm	0 ( 0.0%)	1 ( 0.6%)
SURGICAL AND MEDICAL PROCEDURES	1 ( 0.3%)	0 ( 0.0%)
Lung assist device therapy	1 ( 0.3%)	0 ( 0.0%)
VASCULAR DISORDERS	1 ( 0.3%)	0 ( 0.0%)
Internal haemorrhage	1 ( 0.3%)	0 ( 0.0%)

---